In fact, serum KRAS2 was stronger than the influence of Dukes’ stage or of treatment with adjuvant chemotherapy in the predict of CRC recurrence by a Cox regression multivariate analysis [7]. The gene discussed is KRAS; the disease is colorectal carcinoma.